The burden of diabetes mellitus for medicare beneficiaries

Population Health Management

Volumn 17, Issue 5, 2014, Pages 272-278

  Costantino, Mary E ^a   Stacy, Jane N ^b   Song, Frank ^c   Xu, Yihua ^a   Bouchard, Jonathan R ^d  

^a Comprehensive Health Insights Inc ^*  (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c Blue Cross and Blue Shield of Louisiana   (United States)

^d NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; METFORMIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; ASTHMA; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DYSLIPIDEMIA; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; OUTPATIENT; OUTPATIENT DEPARTMENT; PERIPHERAL VASCULAR DISEASE; PHARMACY; RETINOPATHY; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; CASE CONTROL STUDY; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ECONOMICS; HEALTH SERVICE; UNITED STATES; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MEDICARE; UNITED STATES;

EID: 84907042178     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2013.0097     Document Type: Article

References (35)

1. Mainous AG, Baker R, Koopman RJ, et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: An epidemic on the way. Diabetologia 2007;50:934-940.
2. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006;12(1):62-66.
3. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-1940.
4. Björk S. The cost of diabetes and diabetes care. Diabetes Res Clin Pract 2001;54(suppl 1):S13-S18.
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615.
6. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009;32:2225-2229.
7. Bernard DM, Banthin JS, Encinosa WE. Health care expenditure burdens among adults with diabetes in 2001. Med Care 2006;44:210-215.
8. Fraze TK, Jiang HJ, Burgess J. Hospital stays for patients with diabetes, 2008. HCUP Statistical Brief #93. Available at: . Accessed August 19, 2013.
9. Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care 2008;31:624-625.
10. National Diabetes Data Group. Diabetes in America, 2nd edition. NIH Publication No. 95-1468. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995.
11. Campbell RK. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc (2003) 2009;49 (suppl 1):S3-S9.
12. Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention, 2008.
13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
14. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-259.
15. D'Agostino RB. Propensity scores in cardiovascular research. Circulation 2007;115:2340-2343.
16. Cantoni E, Ronchetti E. A robust approach for skewed and heavy-Tailed outcomes in the analysis of health care costs. J Health Econ 2006;25:198-213.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity use with ICD-9-CM administrative index for databases. J Clin Epidemiol 1992;45:613-619.
18. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
19. Johnson JA, Pohar SL, Majumdar SR. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: A population-based study. Diabetes Care 2006; 29:2403-2408.
20. Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009;12:103-110.
21. Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: A propensity score matching method. PloS One 2010;5(7): E11501-e11501.
22. Tunceli O, Wade R, Gu T, Bouchard JR, Aagren M, Luo W. Cost of diabetes: Comparison of disease-Attributable and matched cohort cost estimation methods. Curr Med Res Opin 2010;26:1827-1834.
23. Hex N, Bartlett C,Wright D, TaylorM, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855-862.
24. Setacci C, de Donato G, Setacci F, Chisci EJ. Diabetic patients: Epidemiology and global impact. J Cardiovasc Surg (Torino) 2009;50:263-273.
25. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010;15:918-922.
26. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research. Appl Health Econ Health Policy 2008;6:103-112.
27. Ariza MA, Vimalananda VG, Rosenzweig JL. The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocr Metab Disord 2010; 11:1-10.
28. Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med 2007;167:921-927.
29. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.
30. Roark RF, Shah BR, Udayakumar K, Peterson ED. The need for transformative innovation in hypertension management. Am Heart J 2011;162:405-411.
31. Brooks PM. The burden of musculoskeletal disease-A global perspective. Clin Rheumatol 2006;25:778-781.
32. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: A retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 2011;17:25-39.
33. Zhang W, Anis AH. The economic burden of rheumatoid arthritis: Beyond health care costs. Clin Rheumatol 2011;30(suppl 1):S25-S32.
34. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304.
35. Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008;168:192-199.